B-type natriuretic peptide in ischemic heart disease

Current Cardiology Reports

Volumn 5, Issue 4, 2003, Pages 271-277

  Deo, Rajat ^a   de Lemos, James A ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLYCERYL TRINITRATE; NESIRITIDE; PLACEBO; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENT; N TERMINAL PROATRIAL NATRIURETIC PEPTIDE; N-TERMINAL PROATRIAL NATRIURETIC PEPTIDE; PROTEIN PRECURSOR;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART STRESS; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; ISCHEMIC HEART DISEASE; PROGNOSIS; REVIEW; STRATIFICATION; TREATMENT OUTCOME; ACUTE DISEASE; BLOOD; HEART INFARCTION; SYNDROME; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PROTEIN PRECURSORS; SYNDROME;

EID: 0642339079     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-003-0062-8     Document Type: Review

References (40)

1. Edwards BS, Zimmerman RS, Schwab TR, et al.: Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 1988, 62:191-195.
2. Yan W, Sheng N, Seto M, et al.: Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 1999, 274:14926-14935.
3. Hooper JD, Scarman AL, Clarke BE, et al.: Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem 2000, 267:6931-6937.
4. Potter LR, Hunter T: Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem 2001, 276:6057-6060.
5. Rademaker MT, Charles CJ, Kosoglou T, et al.: Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol 1997, 273:H2372-H2379.
6. Maisel AS, Koon J, Krishnaswamy P, et al.: Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001, 141:367-374.
7. Lubien E, DeMaria A, Krishnaswamy P, et al.: Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002, 105:595-601.
8. Yu CM, Sanderson JE, Shum IO, et al.: Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996, 17:1694-1702.
9. Dao Q, Krishnaswamy P, Kazanegra R, et al.: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001, 37:379-385.
10. Davis M, Espiner E, Richards C, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994, 343:440 444.
11. Cowie MR, Struthers AD, Wood DA, et al.: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350:1349-1353.
12. Maisel AS, Krishnaswamy P, Nowak RM, et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
13. McCullough PA, Nowak RM, McCord J, et al.: B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002, 106:416-422.
14. Richards AM, Doughty R, Nicholls MG, et al.: Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999, 99:786-792.
15. Maeda K, Tsutamoto T, Wada A, et al.: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000, 36:1587-1593.
16. Stanek B, Frey B, Hulsmann M, et al.: Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001, 38:436-442.
17. Berger R, Huelsman M, Strecker K, et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002, 105:2392-2397.
18. Isnard R, Pousset F, Trochu J, et al.: Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000, 86:417-421.
19. Richards AM, Doughty R, Nicholls MG, et al.: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001, 37:1781-1787.
20. Harrison A, Morrison LK, Krishnaswamy P, et al.: B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002, 39:131-138.
21. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540.
22. Hobbs RE, Mills RM, Young JB: An update on nesiritide for treatment of decompensated heart failure. Expert Opin Investig Drugs 2001, 10:935-942.
23. Colucci WS: Nesiritide for the treatment of decompensated heart failure. J Cardiac Fail 2001, 7:92-100.
24. Colucci WS, Elkayam U, Horton DP, et al.: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000, 343:246-253.
25. Hama N, Itoh H, Shirakami G, et al.: Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995, 92:1558-1564.
26. Toth M, Vuorinen KH, Vuolteenaho O, et al.: Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 1994, 266:H1572-H1580.
27. Marumoto K, Hamada M, Hiwada K: Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci 1995, 88:551-556.
28. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T: Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol 2000, 23:776780.
29. Morita E, Yasue H, Yoshimura M, et al.: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993, 88:82-91.
30. Arakawa N, Nakamura M, Aoki H, Hiramori K: Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 1994, 85:334-340.
31. Talwar S, Squire IB, Downie PF, et al.: Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction. Eur Heart J 2000, 21:1514-1521.
32. Nagaya N, Nishikimi T, Goto Y, et al.: Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998, 135:21-28.
33. Omland T, Aakvaag A, Bonarjee VV, et al.: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996, 93:1963-1969.
34. de Lemos JA, Morrow DA, Bentley JH, et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021.
35. Omland T, de Lemos JA, Morrow DA, et al.: Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002, 89:463-465.
36. Omland T, Persson A, Ng L, et al.: N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002, 106:2913-2918.
37. Jernberg T, Stridsberg M, Venge P, Lindahl B: N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002, 40:437-445.
38. Morrow DA, de Lemos JA, Sabatine MS: Evaluation of B-type natriuretic peptide for risk assessment in UA/NSTEMI: BNP and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003, 41:1264-1272.
39. Cannon CP, Weintraub WS, Demopoulos LA, et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl Med 2001, 344:1879-1887.
40. Morrow DA, Cannon CP, Rifai N, et al.: Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001, 286:2405-2412.